Quinoline oxadiazoles as cytoprotective agents

A method for treating a neurological or neurodegenerative disorder in a subject comprising administering to the subject an effective amount of a compound of Formula I:

• or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof;
• or a pharmaceutically acceptable salt, solvate, or hydrate thereof;
• wherein:
• R2 is methyl;
• R3, R4, R5, R6, and R7 are each independently (a) hydrogen, cyano, or halo or (b) C1-6 alkyl, C3-10 cycloalkyl, or heterocyclyl with the proviso that R3 and R7 are not concurrently C1;
• and
• R1 is aryl or heteroaryl.

A method for treating, preventing, or ameliorating one or more symptoms of diabetes in a subject in need thereof comprising administering to the subject an effective amount of the compound Formula I:

• or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof;
• or a pharmaceutically acceptable salt, solvate, or hydrate thereof;
• wherein:
• R2 is methyl;
• R3, R4, R5, R6, and R7 are each independently (a) hydrogen, cyano, or halo or (b) C1-6 alkyl, C3-10 cycloalkyl, or heterocyclyl with the proviso that R3 and R7 are not concurrently Cl;
• and
• R1 is aryl or heteroaryl.